

## **Immunicum presents continued improvement in phase I/II survival data for INTUVAX-treated renal cancer patients**

**Gothenburg, Sweden, August 4th 2015. Immunicum AB (publ) today announced continued improvement in survival data from the follow-up phase of a clinical phase I/II trial in patients with metastatic renal cell cancer. Seven of eleven evaluable patients are still alive.**

Immunicum reports updated survival data from the Company's phase I/II study in patients with metastatic renal cancer treated with the cancer vaccine INTUVAX. Seven of the 11 patients evaluable for efficacy are still alive. Six of the 11 patients have received add-on treatment with some type of tyrosine kinase inhibitor. Median overall survival for the entire patient group is currently at 26.5 months versus expected 15.2 months (historical data for newly diagnosed patients with metastasized renal cell cancer receiving standard treatment with tyrosine kinase inhibitor Sutent/sunitinib). For the poor prognosis group (6 patients), the median overall survival is currently at 25.5 months versus expected 9 months and for patients with intermediate risk prognosis (5 patients), the median overall survival is currently at 32 months compared to expected 26 months. The final median overall survival has not yet been reached for any of the three patient groups.

- It is very encouraging that the median overall survival for INTUVAX-treated renal cancer patients continues to increase. For the high-risk group, we note a current median overall survival that is close to tripled compared to the expected median overall survival for patients receiving standard treatment with sunitinib. We have now initiated a comprehensive phase II study in the same indication where we, thanks to the open design, expect to be able to provide a first status update around the end of the year, says Immunicum's CEO, Jamal El-Mosleh.

The purpose of the phase I/II study was to document the safety profile and immunological effects, as well as to follow the survival of patients with metastatic renal cell cancer after two INTUVAX treatments.

### **For further information, please contact:**

Jamal El-Mosleh, CEO, Immunicum

Phone: +46 (0) 31 41 50 52  
jamal.el-mosleh@immunicum.com

The Company's Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31. [www.redeye.se](http://www.redeye.se)

## **About Immunicum AB (publ)**

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the Company's most advanced project - INTUVAX® against renal cancer – has been initiated. The project portfolio contains an additional clinical phase I/II project in liver cancer.

[www.immunicum.com](http://www.immunicum.com)